Patent search ap:"WENSHENG YU" Page 6

51.

发明授权
Process for preparing saponin compounds 有权
Title translation: 皂苷化合物的制备方法

公开(公告)号：US06753414B2

公开(公告)日：2004-06-22

申请号：US10213363

申请日：2002-08-06

Applicant: Zhendong Jin , Wensheng Yu

Inventor： Zhendong Jin , Wensheng Yu

IPC: C07H100

CPC classification number: C07J9/00

Abstract: A process for preparing compounds of formula (1): including the convergent steps as defined in the specification, and wherein R groups have any of the values defined in the specification. The invention also provides processes and intermediates useful for preparing compounds of formula (1).

Abstract translation: 制备式（1）化合物的方法：包括说明书中定义的收敛步骤，其中R基团具有说明书中定义的任何值。本发明还提供了可用于制备式（1）化合物的方法和中间体。

52.

发明申请
BTK INHIBITORS 有权
Title translation: BTK抑制剂

公开(公告)号：US20150353570A1

公开(公告)日：2015-12-10

申请号：US14762954

申请日：2014-01-22

Applicant: Hao WU , Ronald M. KIM , Jian LIU , Xiaolei GAO , Sobhana Babu BOGA , Deodialsingh GUIADEEN , Joseph KOZLOWSKI , Wensheng YU , Rajan ANAND , Younong YU , Oleg B. Selyutin , Ying-Duo GAO , Shilan LIU , Chundao YANG , Hongjian WANG , MERCK SHARP & DOHME CORP.

Inventor： RONALD M. KIM , JIAN LIU , XIAOLEI GAO , SOBHANA BABU BOGA , DEODIALSINGH GUIADEEN , JOSEPH A. KOZLOWSKI , WENSHENG WU , RAJAN ANAND , YOUNONG YU , OLEG B. SELYUTIN , YING-DUO GAO , HAO WU , SHILAN LIU , CHUNDAO YANG , HONGJIAN WANG

IPC: C07D491/048 , C07D471/04 , A61K45/06 , A61K31/5383 , C07D455/02 , A61K31/5365 , A61K31/497 , C07D498/04

CPC classification number: C07D491/048 , A61K31/497 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K31/5365 , A61K31/5383 , A61K45/06 , C07D455/02 , C07D471/04 , C07D487/04 , C07D498/04 , C07D519/00 , Y02A50/411 , Y02A50/463

Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

Abstract translation: 本发明提供了根据式I的Bruton's酪氨酸激酶（Btk）抑制剂化合物或其药学上可接受的盐或包含这些化合物的药物组合物及其在治疗中的用途。特别地，本发明涉及Btk抑制剂化合物在治疗Btk介导的病症中的用途。

53.

发明申请
NOVEL SPIRO IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE 审中-公开
Title translation: 作为GLUCAGON受体拮抗剂，组合物及其使用方法的新型SPIRO咪达唑仑衍生物

公开(公告)号：US20130012493A1

公开(公告)日：2013-01-10

申请号：US13636276

申请日：2011-03-22

Applicant: He Zhao , Ping Chen , Peishan Lin , Peng Dai , Jason Louis Davis , Duane E. DeMong , Michael W. Miller , Xing Dai , Michael K. Wong , Brian J. Lavey , Wensheng Yu , Guowei Zhou , Andrew W. Stamford , Joseph A. Kozlowski , William J. Greenlee

Inventor： He Zhao , Ping Chen , Peishan Lin , Peng Dai , Jason Louis Davis , Duane E. DeMong , Michael W. Miller , Xing Dai , Michael K. Wong , Brian J. Lavey , Wensheng Yu , Guowei Zhou , Andrew W. Stamford , Joseph A. Kozlowski , William J. Greenlee

IPC: A61K31/454 , A61P3/10 , C07D403/12 , A61K31/4178 , A61K31/5386 , A61K31/55 , A61K31/496 , C07D413/14 , A61K31/5377 , C07D498/08 , C07D401/14 , C07D403/14

CPC classification number: C07D403/12 , C07D401/04 , C07D401/14 , C07D403/14 , C07D413/04 , C07D413/14 , C07D491/08 , C07D498/08

Abstract: The present invention relates to compounds of the general formula (I): wherein ring A, ring B, G, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

Abstract translation: 本发明涉及通式（I）的化合物：其中环A，环B，G，R 3，Z，L 1和L 2彼此独立地并且如本文所定义，包含该化合物的组合物，和涉及使用该化合物作为胰高血糖素受体拮抗剂并用于治疗或预防2型糖尿病及与之有关的病症的方法。

54.

发明申请
NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE 审中-公开
Title translation: 作为GLUCAGON受体拮抗剂，组合物及其使用方法的新型SPIRO咪唑烷

公开(公告)号：US20130012434A1

公开(公告)日：2013-01-10

申请号：US13636244

申请日：2011-03-22

Applicant: Michael K. Wong , Brian J. Lavey , Wensheng Yu , Joseph A. Kozlowski , Duanc E. DeMong , Xing Dai , Andrew W. Stamford , Michael W. Miller , Guowei Zhou , De-Yi Yang , William J. Greenlee

Inventor： Michael K. Wong , Brian J. Lavey , Wensheng Yu , Joseph A. Kozlowski , Duanc E. DeMong , Xing Dai , Andrew W. Stamford , Michael W. Miller , Guowei Zhou , De-Yi Yang , William J. Greenlee

IPC: A61K31/4184 , C07D235/02 , C07D471/10 , A61K31/438 , C07F7/10 , A61K31/695 , C07D491/107 , C07D487/10 , A61K31/4188 , C07D403/14 , A61K31/497 , A61K31/506 , C07D487/04 , A61K31/4985 , A61K38/28 , A61P3/10 , A61K38/17 , A61K38/26 , A61K31/7034 , A61K31/7048 , A61P3/04 , A61P3/06 , A61P9/10 , C07D403/12

CPC classification number: C07D403/12 , C07D233/70 , C07D401/10 , C07D405/10 , C07F7/0812

Abstract: The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

Abstract translation: 本发明涉及以下通式的化合物：其中环A，环B，R 1，R 3，Z，L 1和L 2彼此独立地并且如本文所定义，包含该化合物的组合物，以及使用该化合物作为胰高血糖素受体拮抗剂，并用于治疗或预防2型糖尿病及与此有关的病症。

55.

发明授权
Compounds for the treatment of inflammatory disorders 有权
Title translation: 用于治疗炎性疾病的化合物

公开(公告)号：US07879890B2

公开(公告)日：2011-02-01

申请号：US12338445

申请日：2008-12-18

Applicant: Wensheng Yu , Ling Tong , Lei Chen , Joseph A. Kozlowski , Brian J. Lavey , Neng-Yang Shih , Vincent S. Madison , Guowei Zhou , Peter Orth , Zhuyan Guo , Michael K. C. Wong , De-Yi Yang , Seong Heon Kim , Bandarpalle B. Shankar , M. Arshad Siddiqui , Kristin E. Rosner , Chaoyang Dai , Janeta Popovici-Muller , Vinay M. Girijavallabhan , Dansu Li , Razia Rizvi , Aneta M. Micula , Robert Feltz

Inventor： Wensheng Yu , Ling Tong , Lei Chen , Joseph A. Kozlowski , Brian J. Lavey , Neng-Yang Shih , Vincent S. Madison , Guowei Zhou , Peter Orth , Zhuyan Guo , Michael K. C. Wong , De-Yi Yang , Seong Heon Kim , Bandarpalle B. Shankar , M. Arshad Siddiqui , Kristin E. Rosner , Chaoyang Dai , Janeta Popovici-Muller , Vinay M. Girijavallabhan , Dansu Li , Razia Rizvi , Aneta M. Micula , Robert Feltz

IPC: A61K31/416 , A61K31/428

CPC classification number: C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/00 , C07D473/34 , C07D487/04 , C07D491/04 , C07D495/04

Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，溶剂化物，酯或异构体，其可用于治疗由MMP，ADAM，TACE，聚集蛋白聚糖酶，TNF-或组合介导的疾病或病症其中。

56.

发明授权
Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity 有权
Title translation: 具有CXCR3拮抗活性的杂芳基取代的吡嗪基 - 哌嗪 - 哌啶

公开(公告)号：US07879838B2

公开(公告)日：2011-02-01

申请号：US11353474

申请日：2006-02-14

Applicant: Qingbei Zeng , De-Yi Yang , Stuart B. Rosenblum , Michael K. C. Wong , Gopinadhan N. Anilkumar , Seong Heon Kim , Wensheng Yu , Joseph A. Kozlowski , Neng-Yang Shih , Brian F. McGuinness , Lisa Guise Zawacki , Doublas W. Hobbs

Inventor： Qingbei Zeng , De-Yi Yang , Stuart B. Rosenblum , Michael K. C. Wong , Gopinadhan N. Anilkumar , Seong Heon Kim , Wensheng Yu , Joseph A. Kozlowski , Neng-Yang Shih , Brian F. McGuinness , Lisa Guise Zawacki , Doublas W. Hobbs

IPC: A01N43/00 , A61K31/00 , A61K31/535 , A61K31/497 , C07D413/00 , C07D403/00 , C07D241/02

CPC classification number: C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/04

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Abstract translation: 本申请公开了所述化合物或所述前药的所述化合物或其对映异构体，立体异构体，旋转异构体，互变异构体，外消旋体或前药，或所述前药的所述化合物，所述化合物具有式1所示的一般结构：和其药学上可接受的盐，溶剂合物或酯。还公开了治疗趋化因子介导的疾病的方法，例如姑息治疗，疗效治疗，某些疾病和疾病如炎性疾病的预防性治疗（非限制性实例，牛皮癣），自身免疫性疾病（非限制性的例如，类风湿性关节炎，多发性硬化症），移植排斥反应（非限制性实例包括，同种异体移植排斥反应，异种移植物排斥），感染性疾病（例如结核性麻风病），固定药物爆发，皮肤迟发型超敏反应应答，眼部炎症，I型糖尿病，病毒性脑膜炎和使用式1的化合物的肿瘤。